参考文献/References:
[1] 段 键,何金兰,曾 仲. 结直肠癌肝转移的多学科团队治疗[J]. 中华消化外科杂志, 2021, 20:1370- 1372.
[2] 姚宏伟,张忠涛. 从全国结直肠癌手术病例数据库论述结直肠癌外科诊断与治疗的规范化[J]. 中华消化外科杂志, 2020,19:55- 58.
[3] Chakedis J, Schmidt CR. Surgical treatment of metastatic colorectal cancer[J]. Surg Oncol Clin N Am, 2018, 27:377- 399.
[4] Zellweger M, Abdelnour- Berchtold E, Krueger T, et al. Surgical treatment of pulmonary metastasis in colorectal cancer patients: current practice and results[J]. Crit Rev Oncol Hematol, 2018, 127: 105- 116.
[5] Dwyer RH, Scheidt MJ, Marshall JS, et al. Safety and efficacy of synchronous robotic surgery for colorectal cancer with liver metastases[J]. J Robot Surg, 2018, 12: 603- 606.
[6] Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National cancer institute’s patient- reported outcomes version of the common terminology criteria for adverse events(PRO- CTCAE)[J]. JAMA Oncol, 2015, 1: 1051- 1059.
[7] 杨 晶,白 彬,徐 伟,等. 晚期结直肠癌的超选择性动脉化疗栓塞治疗[J]. 中国介入影像与治疗学, 2016, 13:647- 677.
[8] Woeste MR, Philips P, Egger ME, et al. Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer[J]. J Surg Oncol, 2020, 121: 1298- 1305.
[9] Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer[J]. Cancer,2019,125:4139- 4147.
[10] Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential[J]. Nat Rev Gastroenterol Hepatol,2019,16:361- 375.
[11] 王克山,阮 玫,孙丽艳,等.阿帕替尼联合雷替曲塞三线治疗晚期结直肠癌患者的临床疗效观察[J]. 中国肿瘤临床与康复, 2019, 26:58- 61.
[12] Johdi NA, Sukor NF. Colorectal cancer immunotherapy: options and strategies[J]. Front Immunol,2020,11:1624.
[13] Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer[J]. Cancer, 2019, 125: 4139- 4147.
[14] 周静文,何明基,练 辉,等. 免疫检查点抑制剂PD- 1免疫相关不良反应的临床分析[J]. 介入放射学杂志, 2021, 30:29- 33.
[15] Shen Z, Wang B, Luo J, et al. Global- scale profiling of differential expressed lysine acetylated proteins in colorectal cancer tumors and paired liver metastases[J]. J Proteomics, 2016, 142:24- 32.
[16] Peng SH, Mbarak HS, Li YH, et al. Neoadjuvant intra- arterial versus intravenous chemotherapy in colorectal cancer[J]. Medicine (Baltimore), 2021, 100:e28312.
[17] Bini R, Comolli S, Leli R, et al. A novel approach to inoperable or recurrent rectal cancer by chemoembolization: a new arrow in our quiver?[J]. Oncotarget,2016,7:45275- 45282.
[18] 方世明,刘玉金,高 峰. 区域性动脉灌注化疗并栓塞对不能手术的恶性肠梗阻的临床应用[J]. 介入放射学杂志, 2016, 25:120- 124.
[19] Nagamitsu A, Konno T, Oda T, et al. Targeted cancer chemo- therapy for VX2 tumour implanted in the colon with lipiodol as a carrier[J]. Eur J Cancer, 1998, 34: 1764- 1769.
[20] Caine M, Chung T, Kilpatrick H, et al.Evaluation of novel formulations for transarterial chemoembolization: combining elements of lipiodol emulsions with drug- eluting beads[J]. Theranostics, 2019, 19:5626- 5641.
相似文献/References:
[1]方 瑜,龙清云,刘骏方,等.肝癌合并肝动脉-肝门静脉瘘介入治疗方式的探讨[J].介入放射学杂志,2010,(10):776.
FANG Yu,LONG Qing-yun,LIU Jun-fang,et al.Exploration of interventional therapeutic pattern for hepatocellular carcinoma associated with hepatic arterioportal fistulae[J].journal interventional radiology,2010,(02):776.
[2]邱伟利,王成刚.肝动脉化疗栓塞治疗转移性肝癌25例分析[J].介入放射学杂志,1997,(03):146.
[3]李茂全.胃癌介入治疗的现状和研究进展[J].介入放射学杂志,1999,(01):54.
[4]张绪敬,程佩芳,董光,等.原发性肝癌经导管化疗、栓塞前后血中凝血酶原变化的研究[J].介入放射学杂志,1992,(01):33.
[5]周文群,刘子江,袁建华,等.动脉内顺铂微球碘化油与抗癌药物碘化油栓塞化疗对肝癌疗效的比较[J].介入放射学杂志,1992,(01):27.
[6]李茂全,颜志平,周康荣,等.中晚期肝癌根治术后介入放射学治疗的临床研究[J].介入放射学杂志,1994,(02):79.
[7]刘古燕,金琰,王树森,等.肠系膜下动脉化疗栓塞致肛门括约肌松驰一例[J].介入放射学杂志,1994,(03):180.
[8]俞进友,朱良志,夏曙祥,等.肝动栓塞治疗肝癌并发癌破裂二例[J].介入放射学杂志,1994,(04):188.
[9]陈雪萍,程永德.肝癌肝动脉化疗栓塞术后影响甲胎蛋白下降因素探讨[J].介入放射学杂志,1995,(02):73.
[10]郝楠馨,贾雨辰,陈庆华,等.甲氨蝶呤明胶微球经肝动脉灌注后近期毒性的实验研究[J].介入放射学杂志,1995,(03):154.